Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Seaport Therapeutics receive regulatory approval for a new drug by 2025?
FDA approval • 25%
EMA approval • 25%
Both FDA and EMA approval • 25%
No approval • 25%
Regulatory agency announcements or Seaport Therapeutics' press releases
Seaport Therapeutics Secures $225M in Oversubscribed Series B Round Led by General Atlantic
Oct 21, 2024, 06:14 AM
Seaport Therapeutics, a company founded by PureTech, has successfully closed a $225 million oversubscribed Series B financing round. The financing round was led by General Atlantic and includes an impressive group of investors. The funds will be used to advance Seaport Therapeutics' efforts in developing better medicines for depression, anxiety, and other neuropsychiatric disorders. This significant investment comes as the company aims to embrace what it describes as the 'golden age of neuroscience.' SeaportTx announced the news.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $1 billion • 25%
Above $3 billion • 25%
$2 billion to $3 billion • 25%
$1 billion to $2 billion • 25%